Susan Treves Selected Research

Central Core Myopathy (Central Core Disease)

1/2020	Bi-allelic expression of the RyR1 p.A4329D mutation decreases muscle strength in slow-twitch muscles in mice.
2/2015	Characterization of excitation-contraction coupling components in human extraocular muscles.
2/2011	Enhanced excitation-coupled Ca(2+) entry induces nuclear translocation of NFAT and contributes to IL-6 release from myotubes from patients with central core disease.
7/2010	Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
2/2009	A recessive ryanodine receptor 1 mutation in a CCD patient increases channel activity.
6/2008	Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm.
8/2007	Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies.
1/2007	Functional effects of mutations identified in patients with multiminicore disease.
1/2007	Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation-contraction (EC) coupling by distinct mechanisms.
4/2006	Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susan Treves Research Topics

Disease

23	Muscular Diseases (Myopathy) 01/2022 - 09/2006
19	Malignant Hyperthermia 01/2022 - 10/2004
13	Central Core Myopathy (Central Core Disease) 01/2020 - 02/2003
10	Minicore Myopathy with External Ophthalmoplegia 01/2020 - 10/2005
7	Congenital Structural Myopathies (Centronuclear Myopathy) 01/2021 - 04/2007
4	Muscle Weakness 01/2022 - 08/2007
4	Rhabdomyolysis 01/2022 - 01/2020
4	Ophthalmoplegia (External Ophthalmoplegia) 01/2020 - 01/2007
3	Contracture 01/2022 - 11/2011
2	Infections 01/2022 - 12/2008
2	Fatigue 08/2021 - 01/2012
2	Hemorrhage 08/2021 - 01/2016
2	Myalgia 01/2018 - 01/2016
2	Paralysis (Palsy) 01/2018 - 03/2010
1	Acute Abdomen 01/2022
1	Fever (Fevers) 01/2022
1	Muscle Cramp (Cramp) 01/2022
1	Neuroleptic Malignant Syndrome 01/2022
1	Wounds and Injuries (Trauma) 01/2022
1	Heat Stress Disorders (Heat Cramp) 01/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2022
1	Serotonin Syndrome (Syndrome, Serotonin) 01/2022
1	Pain (Aches) 08/2021
1	Atrophy 01/2020
1	Brody myopathy 01/2020
1	Myoglobinuria 01/2016
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2016
1	Nemaline Myopathies (Nemaline Myopathy) 08/2015
1	Hypersensitivity (Allergy) 01/2013
1	Obesity 04/2012
1	1 Rippling muscle disease 03/2011
1	Neoplasms (Cancer) 09/2007
1	Myasthenia Gravis 01/2003

Drug/Important Bio-Agent (IBA)

37	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2022 - 01/2003
10	CalciumIBA 01/2020 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2003
3	RyanodineIBA 01/2022 - 11/2011
3	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022 - 01/2016
2	Succinylcholine (Suxamethonium Chloride)FDA LinkGeneric 01/2022 - 01/2016
2	LipidsIBA 01/2022 - 01/2017
2	MethyltransferasesIBA 01/2022 - 01/2019
2	Anesthetics (Anesthetic Agents)IBA 01/2022 - 01/2016
2	Dantrolene (Dantrium)FDA LinkGeneric 01/2022 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2017
2	Calcium Channels (Calcium Channel)IBA 01/2017 - 06/2008
2	EnzymesIBA 01/2017 - 01/2007
2	Interleukin-6 (Interleukin 6)IBA 02/2011 - 10/2004
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Illicit Drugs (Recreational Drugs)IBA 01/2022
1	Antipsychotic Agents (Antipsychotics)IBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	Selenoproteins (Selenoprotein)IBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2017
1	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 01/2017
1	myotubularinIBA 01/2017
1	UtrophinIBA 01/2016
1	Small Interfering RNA (siRNA)IBA 08/2015
1	MicroRNAs (MicroRNA)IBA 08/2015
1	Neuropeptide YIBA 04/2012
1	Protein Isoforms (Isoforms)IBA 03/2011
1	RNA Splice SitesIBA 03/2011
1	Caveolin 3IBA 03/2011
1	CaveolinsIBA 03/2011
1	AntigensIBA 12/2008
1	aspartic acid 2-oxoglutarate-dependent dioxygenaseIBA 09/2007
1	Caffeine (No Doz)FDA LinkGeneric 10/2004
1	CytokinesIBA 10/2004
1	Amino Acids FDA Link 02/2003
1	EpitopesIBA 01/2003
1	AntibodiesIBA 01/2003
1	Immunoglobulin G (IgG)IBA 01/2003

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2017
1	Anesthesia 01/2022
1	Preoperative Exercise 01/2022
1	General Anesthesia 01/2022
1	Activities of Daily Living (ADL) 08/2021